• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[局部晚期子宫颈癌(国际妇产科联盟TNM分期IIB-IIIB期):放疗联合每日低剂量铂同步治疗。II期研究]

[Locally advanced carcinoma of the cervix uteri (stage IIB-IIIB TNM-UICC): radiotherapy combined with simultaneous daily low-dose platinum. Phase II study].

作者信息

Micheletti E, La Face B, Bianchi E, Cagna E, Sartori E

机构信息

Istituto del Radio O. Alberti, Cattedra di Radioterapia, Università di Brescia.

出版信息

Radiol Med. 1996 May;91(5):628-34.

PMID:8693131
Abstract

A prospective, single arm, phase-II trial was performed to assess the efficacy and local toxicity of the combination of low doses of platin and pelvic radiotherapy in patients with locally advanced carcinoma of the cervix. January, 1993, through August, 1994, twenty-three previously untreated patients with squamous carcinoma (stages IIB-IIIB UICC) entered the study. All patients were examined by a gynecologist and by a radiation oncologist and then submitted to conventional pretreatment staging procedures. Nine patients were classified as stage IIB and 14 patients as stage IIIB. Radiotherapy consisted of 60 Gy external beam irradiation (46 Gy to pelvis + 14 Gy boost to cervix uteri and parametria) plus one low dose rate intracavitary treatment to a dose of 8 Gy to point A. Cisplatin (3 mg/m2/day) or carboplatin (12 mg/m2/day) was also given for 6 weeks starting on radiotherapy day 1. The treatment was well tolerated and no patient required radiotherapy discontinuation. With a median follow-up time of 20 months, complete response was seen in 74% (17/23) of the patients. One of the 17 patients who achieved a complete remission, during follow-up, relapsed in the pelvis and one developed lung metastases. Total failure rate in the pelvis was 30.5% (7/23). Distant metastases were observed in 17.5% (4/23) of the patients. Actuarial overall and disease-free survival rates at 33 months were 69.1% and 65.2%, respectively. Late gastrointestinal toxicity (grade 3) occurred in 8.6% (2/23) of patients, with one patient developing a rectal ulcer-which was submitted to colostomy- and one patient a vaginal necrosis. The combination of platin and radiotherapy appears to be an effective regimen for the patients with locally advanced carcinoma of the cervix and caused a relatively low rate of late gastrointestinal complications.

摘要

进行了一项前瞻性单臂II期试验,以评估低剂量铂与盆腔放疗联合应用于局部晚期宫颈癌患者的疗效和局部毒性。1993年1月至1994年8月,23例先前未接受过治疗的鳞状细胞癌患者(UICC IIB-IIIB期)进入该研究。所有患者均由妇科医生和放射肿瘤学家进行检查,然后接受常规的预处理分期程序。9例患者被分类为IIB期,14例患者为IIIB期。放疗包括60 Gy的外照射(盆腔46 Gy + 子宫颈和宫旁组织14 Gy的加量照射)加一次低剂量率腔内治疗,A点剂量为8 Gy。从放疗第1天开始,顺铂(3 mg/m²/天)或卡铂(12 mg/m²/天)也给予6周。治疗耐受性良好,没有患者需要中断放疗。中位随访时间为20个月,74%(17/23)的患者出现完全缓解。17例达到完全缓解的患者中,有1例在随访期间盆腔复发,1例发生肺转移。盆腔总失败率为30.5%(7/23)。17.5%(4/23)的患者出现远处转移。33个月时的精算总生存率和无病生存率分别为69.1%和65.2%。8.6%(2/23)的患者发生晚期胃肠道毒性(3级),1例患者出现直肠溃疡(接受结肠造口术),1例患者出现阴道坏死。铂与放疗联合似乎是局部晚期宫颈癌患者的有效治疗方案,且导致的晚期胃肠道并发症发生率相对较低。

相似文献

1
[Locally advanced carcinoma of the cervix uteri (stage IIB-IIIB TNM-UICC): radiotherapy combined with simultaneous daily low-dose platinum. Phase II study].[局部晚期子宫颈癌(国际妇产科联盟TNM分期IIB-IIIB期):放疗联合每日低剂量铂同步治疗。II期研究]
Radiol Med. 1996 May;91(5):628-34.
2
High complete response rate of concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the uterine cervix.同步放化疗对局部晚期子宫颈鳞状细胞癌的完全缓解率高。
Gynecol Oncol. 1996 Apr;61(1):101-8. doi: 10.1006/gyno.1996.0105.
3
Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC). A phase I/II and pharmacokinetic study.在子宫颈鳞状细胞癌IIB-IIIB期(国际妇产科联盟[UICC])的常规放射治疗期间持续输注卡铂。一项I/II期及药代动力学研究。
Am J Clin Oncol. 1997 Dec;20(6):613-20. doi: 10.1097/00000421-199712000-00017.
4
Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.紫杉醇和顺铂同期放化疗联合巩固化疗治疗局部晚期宫颈鳞状细胞癌:Ⅱ期研究的初步结果。
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):821-7. doi: 10.1016/j.ijrobp.2009.08.069. Epub 2010 Mar 6.
5
Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.每周一次紫杉醇、每周一次卡铂及同步放疗用于原发性宫颈癌的I期临床试验。
Gynecol Oncol. 2005 Jan;96(1):168-72. doi: 10.1016/j.ygyno.2004.09.009.
6
Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix.同步放疗联合紫杉醇/卡铂化疗作为子宫颈鳞状细胞癌的根治性治疗方法。
Gynecol Oncol. 2007 Jan;104(1):95-9. doi: 10.1016/j.ygyno.2006.07.021. Epub 2006 Sep 22.
7
[Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)].151例局部晚期宫颈癌(T2b-N1、T3b、M0)初始化疗的随机试验
Bull Cancer. 1990;77(10):1007-24.
8
Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix.一项关于顺铂同步盆腔放疗用于局部晚期宫颈癌的II期试验的成熟结果。
Gynecol Oncol. 1996 Jun;61(3):416-22. doi: 10.1006/gyno.1996.0166.
9
A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.拓扑替康联合标准剂量顺铂及同步原发灶放疗用于局部晚期宫颈癌的可行性研究。
Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029. Epub 2008 Nov 1.
10
Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia.多机构合作的东亚和东南亚局部晚期宫颈癌同期放化疗 II 期临床研究。
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):751-7. doi: 10.1016/j.ijrobp.2009.06.011. Epub 2009 Oct 14.

引用本文的文献

1
Phase II Study of a Platinum-Based Adapted Chemotherapy Regimen Combined with Radiotherapy in Patients 75 Years and Older with Esophageal Cancer.铂类改良化疗方案联合放疗用于75岁及以上老年食管癌患者的II期研究
Drugs Aging. 2015 Jun;32(6):487-93. doi: 10.1007/s40266-015-0275-8.